|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2006-9-11
|
|
pubmed:abstractText |
Recent studies have shown a beneficial impact of fluoroquinolones on infection-related morbidity and mortality for patients with haematological malignancies during neutropenia. Among the fluoroquinolones moxifloxacin currently provides one of the broadest spectra of antibacterial activity and may be suitable for prophylaxis during neutropenia.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0305-7453
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
58
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
891-4
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16880172-Anti-Infective Agents,
pubmed-meshheading:16880172-Antibiotic Prophylaxis,
pubmed-meshheading:16880172-Aza Compounds,
pubmed-meshheading:16880172-Bacteremia,
pubmed-meshheading:16880172-Clostridium difficile,
pubmed-meshheading:16880172-Enterocolitis, Pseudomembranous,
pubmed-meshheading:16880172-Fluoroquinolones,
pubmed-meshheading:16880172-Gram-Negative Bacteria,
pubmed-meshheading:16880172-Gram-Positive Bacteria,
pubmed-meshheading:16880172-Humans,
pubmed-meshheading:16880172-Neutropenia,
pubmed-meshheading:16880172-Ofloxacin,
pubmed-meshheading:16880172-Quinolines
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Moxifloxacin prophylaxis in neutropenic patients.
|
|
pubmed:affiliation |
Department of Medical Microbiology and Hygiene, University Hospital, Ulm, Germany.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
